More Effective Therapeutic Targeting Of High Risk Childhood Cancer: Neuroblastoma As A Model
Funder
National Health and Medical Research Council
Funding Amount
$6,601,220.00
Summary
Cancer is the commonest cause of death from disease in Australian children. Childhood neuroblastoma is a particularly aggressive cancer, for which new treatment approaches are urgently needed. The team aims to discover better safer therapies for children with this cancer, conducting clinical trials using new drugs and novel drug combinations. We will also investigate novel ways of targeting neuroblastoma cells and identify therapeutic targets in neuroblastoma-initiating cells.
Improved Outcomes For Children With Cancer Through Improved Target Identification And Drug Discovery: Neuroblastoma As A Model
Funder
National Health and Medical Research Council
Funding Amount
$6,394,247.00
Summary
The majority of children with neuroblastoma still die of their disease, and survivors have serious side-effects of cancer treatment. We aim to discover better therapies for children with this cancer, conducting clinical trials using existing and new drugs in novel combinations. We will also investigate novel ways of targeting neuroblastoma cells, and study possible prevention strategies for this and other embryonal cancers. This work will have application in other childhood and adult cancers.
Depressive And Bipolar Disorders: Causes, Presentation And Treatment Innovations
Funder
National Health and Medical Research Council
Funding Amount
$7,100,605.00
Summary
Depression and bipolar disorder are two of Australia’s leading causes of disease burden, with 3-4 million Australians affected during their lifetime. However, despite being such a serious health burden, there are major shortcomings to current understanding and management. This research program aims to further our knowledge of the causes and presentations of the mood disorders, and to improve and “tailor” treatment for the many Australians who suffer from these highly disabling illnesses.
Stroke outcomes directly relate to brain tissue rescue. We have contributed to changes in clinical practice through many clinical trials of new protocols and therapeutic strategies. Our program will focus on brain salvage in the pre-hospital setting and the acute hospital environment. We will use novel approaches to enhance brain recovery and design new implementation strategies to maximise the benefits of these therapeutic advances.